Javier Morales, MD, FACP, FACE - Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.